Mlb All News Today

Brexu-cel showed efficacy in eliciting both CNS and systemic responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Refusing to quash an FIR lodged against the Vice Chancellor and other higher officials of the Sam Higginbottom University of Agriculture Technology and Science (SHUATS) accused of persuading a woman...

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.

The measure of total DNA in leukemic cells as defined by a DNA index outperformed other criteria for identifying patients with hyperdiploid acute lymphoblastic leukemia (ALL) and favorable prognosis.

Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Jae Park shares his experience with using brexucabtagene autoleucel for patients with relapsed/refractory B-cell acute lymphoblastic leukemia in clinical practice since its FDA approval in October 2021.

Jae Park, MD, explains how real-world CAR T-cell therapy data in patients with relapsed/refractory B-cell acute lymphoblastic leukemia shows high response rates but emphasizes the ongoing need for optimizing toxicity management, with trends toward earlier treatment and cell collection.

Dr Jae Park details the treatment options for relapsed/refractory B-cell acute lymphoblastic leukemia, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, with the treatment choice dependent on patient factors like comorbidities, disease burden, and transplant status.

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.